Xencor (NASDAQ:XNCR) Trading Down 4.5% on Analyst Downgrade

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) fell 4.5% on Tuesday after BTIG Research lowered their price target on the stock from $56.00 to $38.00. BTIG Research currently has a buy rating on the stock. Xencor traded as low as $19.01 and last traded at $19.21. 131,140 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 695,809 shares. The stock had previously closed at $20.11.

Other research analysts have also issued reports about the company. Mizuho lowered their target price on Xencor from $59.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, January 22nd. StockNews.com raised Xencor from a "sell" rating to a "hold" rating in a research report on Saturday, March 9th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $32.00 target price on shares of Xencor in a research report on Wednesday, February 28th. Wedbush lowered their target price on Xencor from $36.00 to $34.00 and set an "outperform" rating for the company in a research report on Wednesday, February 28th. Finally, BMO Capital Markets lowered their price objective on Xencor from $38.00 to $34.00 and set an "outperform" rating for the company in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.00.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 54,108 shares of the firm's stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the completion of the sale, the vice president now directly owns 161,675 shares in the company, valued at approximately $3,133,261.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, VP John R. Desjarlais sold 1,280 shares of the firm's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $30,080.00. Following the completion of the sale, the vice president now directly owns 186,433 shares in the company, valued at approximately $4,381,175.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP John R. Desjarlais sold 54,108 shares of the firm's stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the completion of the sale, the vice president now owns 161,675 shares of the company's stock, valued at $3,133,261.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,351 shares of company stock valued at $2,152,417. Corporate insiders own 4.97% of the company's stock.

Institutional Trading of Xencor

Large investors have recently made changes to their positions in the company. Parallel Advisors LLC boosted its stake in Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 1,015 shares during the last quarter. CWM LLC boosted its stake in Xencor by 498.7% during the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 1,147 shares during the last quarter. Signaturefd LLC boosted its stake in Xencor by 367.7% during the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,151 shares during the last quarter. BluePath Capital Management LLC acquired a new position in Xencor during the 3rd quarter valued at about $31,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 756 shares during the last quarter.

Xencor Price Performance

The business has a 50 day simple moving average of $22.24 and a 200-day simple moving average of $20.40. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -9.01 and a beta of 0.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of $0.36 by ($0.67). The business had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business's revenue was up 106.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) earnings per share. Equities research analysts expect that Xencor, Inc. will post -3.25 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.